Medline’s (MDLN) “Buy” Rating Reaffirmed at BTIG Research

Medline (NASDAQ:MDLN)‘s stock had its “buy” rating restated by stock analysts at BTIG Research in a research note issued to investors on Thursday, Benzinga reports. They currently have a $55.00 price objective on the stock. BTIG Research‘s target price would indicate a potential upside of 36.31% from the company’s previous close.

Several other equities analysts have also recently issued reports on the company. Wells Fargo & Company decreased their price objective on Medline from $45.00 to $34.00 and set an “equal weight” rating for the company in a research note on Tuesday, August 11th. William Blair reiterated an “outperform” rating on shares of Medline in a report on Wednesday, September 23rd. Stifel Nicolaus reduced their target price on shares of Medline from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Truist Financial reduced their price target on shares of Medline from $56.00 to $47.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Finally, TD Cowen cut their price target on Medline from $53.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, August 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Medline has a consensus rating of “Moderate Buy” and an average price target of $46.54.

Medline Price Performance

MDLN opened at $40.35 on Thursday. The business’s fifty day simple moving average is $34.58 and its 200-day simple moving average is $39.53. The company has a current ratio of 4.33, a quick ratio of 2.61 and a debt-to-equity ratio of 0.66. Medline has a 12-month low of $31.37 and a 12-month high of $50.88. The company has a market capitalization of $53.05 billion and a price-to-earnings ratio of 51.08.

Medline (NASDAQ:MDLN) last issued its earnings results on Wednesday, November 4th. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.32 by $0.12. The company had revenue of $7.86 billion during the quarter. On average, equities research analysts anticipate that Medline will post 1.49 earnings per share for the current fiscal year.

Insider Transactions at Medline

In other news, major shareholder Private Ltd Gic sold 2,088,987 shares of Medline stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $35.05, for a total transaction of $73,218,994.35. Following the transaction, the insider owned 16,453,806 shares in the company, valued at approximately $576,705,900.30. The trade was a 11.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 8,538,960 shares of company stock worth $302,807,442 in the last 90 days. Corporate insiders own 0.81% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC lifted its position in Medline by 8.4% during the first quarter. Janus Henderson Group PLC now owns 11,451,861 shares of the company’s stock valued at $506,546,000 after buying an additional 887,240 shares during the period. Banque Pictet & Cie SA increased its holdings in Medline by 2.0% in the 3rd quarter. Banque Pictet & Cie SA now owns 7,455,089 shares of the company’s stock valued at $258,692,000 after acquiring an additional 142,939 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its position in Medline by 233.3% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 5,000,000 shares of the company’s stock valued at $222,500,000 after purchasing an additional 3,500,000 shares during the last quarter. Bessemer Group Inc. increased its position in Medline by 39,404.0% during the first quarter. Bessemer Group Inc. now owns 3,504,006 shares of the company’s stock valued at $155,929,000 after acquiring an additional 3,495,136 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Medline by 30,255.5% during the third quarter. Allspring Global Investments Holdings LLC now owns 2,700,425 shares of the company’s stock worth $94,353,000 after purchasing an additional 2,691,529 shares during the last quarter.

Key Headlines Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported Q3 EPS of $0.44, versus the $0.32 consensus estimate, on revenue of $7.86 billion. Reports said the company raised its full-year growth outlook, helping drive a favorable market response to the results. Medline Q3 2026: EPS beats by 27%, full-year growth outlook raised Medline Q3 Net Sales Rise – Shares Up Pre-Bell
• Positive Sentiment: Medline announced a $1 billion share-buyback program. Repurchases can support per-share results and signal management’s confidence, though the impact depends on timing and execution. Medline posts best intraday gain after Q3 beat, $1B share buybacks
• Neutral Sentiment: The company plans to raise prices in 2027 to offset inflationary pressures. This may help protect margins, but the effect will depend on customers’ acceptance and Medline’s ability to manage costs. Medline plans to increase prices in 2027, reports strong Q3 results
• Negative Sentiment: One report said quarterly profit fell, although Medline reaffirmed its FY2026 adjusted EBITDA outlook. The profit decline tempers the headline EPS beat. Medline Q3 Profit Falls, Reaffirms FY26 Adj. EBITDA Outlook; Shares Up
• Negative Sentiment: A law firm announced an investigation into potential securities-law violations following reported product-quality concerns and stock drops. This is an allegation and investigation, not a finding of wrongdoing, but it adds legal and reputational uncertainty. MDLN Investigation Reminder

Medline Company Profile

Medline Industries, Inc is a medical-supply manufacturer and distributor headquartered in Northfield, Illinois. The company provides products and supply-chain services to healthcare organizations, including hospitals, ambulatory surgery centers, physician offices, long-term care facilities, home health providers and other care settings.

Its product portfolio includes medical-surgical supplies, surgical and operating-room products, patient-care items, examination gloves, protective apparel, laboratory products, respiratory-care equipment, durable medical equipment and products for infection prevention.